Enliven Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 46
- Market Cap
- $1B
- Introduction
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
Clinical Trials
11
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
- Conditions
- CML (Chronic Myelogenous Leukemia)Chronic Phase CML
- Interventions
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT06787144
- Locations
- 🇯🇵
The University of Osaka Hospital, Suita-shi, Osaka, Japan
🇯🇵Akita University Hospital, Akita-shi, Akita-ken, Japan
🇯🇵Aiiku Hospital, Sapporo, Hokkaido, Japan
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- Conditions
- HER2-positive Gastric CancerColorectal CancerHER2 AmplificationHER2-positive Breast CancerHER2 Positive Solid Tumors
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇺🇸
BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
- Conditions
- HER2 Mutant Non-small Cell Lung CancerHER2-positive Metastatic Breast CancerHER2 Gene MutationHER2 Amplification
- Interventions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 198
- Registration Number
- NCT05650879
- Locations
- 🇺🇸
University of Colorado - Anschutz Medical Campus - PPDS, Aurora, Colorado, United States
🇺🇸Advent Health Orlando, Orlando, Florida, United States
🇺🇸BRCR Medical Center Inc, Plantation, Florida, United States
A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Enliven Therapeutics Inc.
- Target Recruit Count
- 200
- Registration Number
- 2023-503335-18-00
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Oregon Health & Science University-Knight Cardiovascular Institute, Portland, Oregon, United States
News
CML Treatment Market Poised for Significant Growth Through 2032 Amid Wave of Recent FDA Approvals
The chronic myelogenous leukemia treatment market is expected to experience significant growth through 2032, driven by increasing disease prevalence and multiple recent FDA approvals.
FDA Approves New Cancer Treatments Amidst Rising Global Cancer Rates
• The FDA issued 16 oncology approvals between July and September 2024, addressing the global surge in cancer cases, particularly among individuals under 50. • Oncolytics Biotech is advancing pelareorep, with plans to submit a clinical trial for HR+/HER2- breast cancer to the FDA in early 2025, following positive BRACELET-1 trial results. • AbbVie has submitted a BLA for telisotuzumab vedotin for previously treated non-small cell lung cancer (NSCLC) with c-Met protein overexpression. • HUTCHMED's partner, Takeda, received approval in Japan for FRUZAQLA (fruquintinib) for previously treated metastatic colorectal cancer (CRC).
Enliven Therapeutics' ELVN-001 Shows Promising Phase 1 Data in Chronic Myeloid Leukemia
Enliven Therapeutics announced updated Phase 1 data for ELVN-001, presented at the ESH-iCMLf conference, showing clinical benefit in heavily pretreated CML patients.